Caruthers Mackenzie, Kothari Shaili, Kelly Conor, Jordan Kim M, Luna Branden
Internal Medicine, OhioHealth Riverside Methodist Hospital, Columbus, USA.
Critical Care Medicine, OhioHealth Riverside Methodist Hospital, Columbus, USA.
Cureus. 2025 May 16;17(5):e84241. doi: 10.7759/cureus.84241. eCollection 2025 May.
Hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition resulting in erroneous activation of the immune system. Treatment is directed at the underlying pathology that prompts activation of the immune system and usually includes immunosuppressant therapy, including steroids, etoposide, or rituximab. However, the best treatment for patients with significant infection remains unclear. Few cases of HLH are associated with disseminated histoplasmosis, and there are no clear treatment guidelines in these cases. Due to the significant morbidity and mortality associated with HLH, further investigation is needed to identify the best treatment regimens.
噬血细胞性淋巴组织细胞增生症（HLH）是一种罕见的高炎症性疾病，会导致免疫系统错误激活。治疗针对促使免疫系统激活的潜在病理状况，通常包括免疫抑制治疗，如使用类固醇、依托泊苷或利妥昔单抗。然而，对于伴有严重感染的患者，最佳治疗方法仍不明确。很少有HLH病例与播散性组织胞浆菌病相关，且在这些病例中没有明确的治疗指南。鉴于HLH相关的高发病率和死亡率，需要进一步研究以确定最佳治疗方案。
